The Food and Drug Administration (FDA) issued a request for information (RFI) seeking input on the design and safety of early-phase clinical trials of ibogaine, a psychedelic compound being studied for potential treatment of substance use and other mental health conditions (press release). FDA is considering approaches to patient selection, dosing and dose escalation, clinical settings, cardiac and neurologic safety… (Colocho, October 5, 2026) #Food and Drug Administration, #Mental and Behavioral Health